Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
13.82
+0.06 (0.44%)
At close: Jul 3, 2025, 1:00 PM
13.77
-0.05 (-0.36%)
After-hours: Jul 3, 2025, 4:59 PM EDT
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 342 employees as of December 31, 2024. The number of employees increased by 46 or 15.54% compared to the previous year.
Employees
342
Change (1Y)
46
Growth (1Y)
15.54%
Revenue / Employee
$622,278
Profits / Employee
-$379,289
Market Cap
1.65B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ARQT News
- 3 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction - Seeking Alpha
- 10 days ago - Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis - GlobeNewsWire
- 11 days ago - Arcutis Biotherapeutics: Another Approval Under Their Belt - Seeking Alpha
- 24 days ago - Arcutis: Out Of The Woods, Ready For Commercialization - Seeking Alpha
- 26 days ago - Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis - GlobeNewsWire
- 4 weeks ago - Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference - GlobeNewsWire
- 4 weeks ago - Arcutis Biotherapeutics: Navigating Commercialization With Promising Upside - Seeking Alpha